Can Neoadjuvant Chemoradiotherapy Combined with Immunotherapy Benefit Patients with Microsatellite Stable Locally Advanced Rectal Cancer? a Pooled and Integration Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Oct 23

PMID 37869097

Authors

Yumin Yue

Min Cheng

XiaoHui Xi

Quan Wang

Mingtian Wei

Bobo Zheng

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the clinical efficacy of neoadjuvant chemoradiotherapy combined with immunotherapy for patients with microsatellite stable (MSS) locally advanced rectal cancer and provide evidence to support clinical decision-making.

Methods: A systematic search was conducted on the PubMed, Embase, Cochrane Collaboration databases, conference summaries, and Chinese databases for clinical studies that investigated neoadjuvant chemoradiotherapy combined with immunotherapy for the treatment of locally advanced rectal cancer with MSS status. The search spanned from the inception of each database through July 2023. Data from the identified studies were extracted using a pre-designed table, and efficacy outcomes were analyzed. An integrated analysis was conducted using Stata 12.0 software.

Results: Eight studies were included, comprising 204 patients with locally advanced MSS rectal cancer who received chemoradiotherapy combined with immunotherapy. The integrated analysis revealed a pathologic complete remission rate of 0.33, a sphincter preservation rate of 0.86, an R0 resection rate of 0.83, a major pathologic remission rate of 0.33, and a clinical complete remission rate of 0.30.

Conclusion: Neoadjuvant chemoradiotherapy combined with immunotherapy demonstrates significant short-term efficacy in MSS-type locally advanced rectal cancer, notably enhancing the pathologic complete remission and sphincter preservation rates. This combination is a recommended treatment for patients with MSS-type rectal cancer.

Citing Articles

Diffusion-Weighted MRI as a Quantitative Imaging Biomarker in Colon Tumors.

Otto P, Loft M, Rafaelsen S, Pedersen M Cancers (Basel). 2024; 16(1).

PMID: 38201571 PMC: 10778248. DOI: 10.3390/cancers16010144.

References

Hofheinz R, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann J . Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012; 13(6):579-88. DOI: 10.1016/S1470-2045(12)70116-X. View

Lin Z, Cai M, Zhang P, Li G, Liu T, Li X . Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer. 2021; 9(11). PMC: 8562535. DOI: 10.1136/jitc-2021-003554. View

Li Y, Zhang L, Dong Q, Cai Y, Zhang Y, Wang L . [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021; 24(11):998-1007. DOI: 10.3760/cma.j.cn441530-20210927-00386. View

Ding P . [Immunotherapy for microsatellite-instability-high advanced colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2022; 25(3):199-204. DOI: 10.3760/cma.j.cn441530-20220118-00025. View

Rahma O, Yothers G, Hong T, Russell M, You Y, Parker W . Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021; 7(8):1225-1230. PMC: 8251652. DOI: 10.1001/jamaoncol.2021.1683. View

Wang Y, Shen L, Wan J, Zhang H, Wu R, Wang J . Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation. Front Immunol. 2022; 13:1067036. PMC: 9772444. DOI: 10.3389/fimmu.2022.1067036. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Bachet J, Benoist S, Mas L, Huguet F . [Neoadjuvant treatment for rectal cancer]. Bull Cancer. 2021; 108(9):855-867. DOI: 10.1016/j.bulcan.2021.03.018. View

Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S . The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treat Rev. 2016; 51:19-26. DOI: 10.1016/j.ctrv.2016.10.005. View

10.

Body A, Prenen H, Lam M, Davies A, Tipping-Smith S, Lum C . Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. Clin Colorectal Cancer. 2021; 20(1):29-41. DOI: 10.1016/j.clcc.2020.12.005. View

11.

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

12.

Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K . Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017; 280(1):249-279. DOI: 10.1111/imr.12573. View

13.

Xiong K, Bao T, Cao Y, Hu W, Deng J, Chen J . Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis. Int J Colorectal Dis. 2023; 38(1):89. DOI: 10.1007/s00384-023-04376-y. View

14.

Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y . Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol. 2022; 13:795972. PMC: 8968082. DOI: 10.3389/fimmu.2022.795972. View

15.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

16.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019; 5(10):1411-1420. PMC: 6659167. DOI: 10.1001/jamaoncol.2019.2187. View

17.

Cohen R, Rousseau B, Vidal J, Colle R, Diaz Jr L, Andre T . Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol. 2019; 15(1):11-24. DOI: 10.1007/s11523-019-00690-0. View

18.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B . Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006; 119(2):317-27. DOI: 10.1002/ijc.21775. View

19.

Habr-Gama A, Perez R, Nadalin W, Sabbaga J, Ribeiro Jr U, Silva e Sousa Jr A . Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004; 240(4):711-7. PMC: 1356472. DOI: 10.1097/01.sla.0000141194.27992.32. View

20.

Marco M, Zhou L, Patil S, Marcet J, Varma M, Oommen S . Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum. 2018; 61(10):1146-1155. PMC: 6130918. DOI: 10.1097/DCR.0000000000001207. View